TM-38837

From Wikipedia, the free encyclopedia
Jump to: navigation, search
TM-38837.svg
Systematic (IUPAC) name
1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
Clinical data
Legal status ?
Identifiers
ATC code None
PubChem CID 49779607
Chemical data
Formula C30H25Cl2F3N4OS 
Mol. mass 617.51 g/mol

TM38837 is a new small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma.[1] The company has announced phase I clinical trials.

TM38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists, for example rimonabant.[2]

See also[edit]

References[edit]

  1. ^ http://www.7tm.com
  2. ^ Hung, M. S.; Chang, C. P.; Li, T. C.; Yeh, T. K.; Song, J. S.; Lin, Y.; Wu, C. H.; Kuo, P. C.; Amancha, P. K.; Wong, Y. C.; Hsiao, W. C.; Chao, Y. S.; Shia, K. S. (2010). "Discovery of 1-(2,4-Dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a Potential Peripheral Cannabinoid-1 Receptor Inverse Agonist". ChemMedChem 5 (9): 1439–1443. doi:10.1002/cmdc.201000246. PMID 20652930.  edit

External links[edit]

  • [1] www.7tm.com
  • [2] Experimental obesity drug avoids brain effects that troubled predecessors